Endocrine Connections, 2018 The dopaminergic treatment represents the primary treatment in prolactinomas, which are the most common pituitary adenomas and account for about 40% of all pituitary tumours with an annual incidence of six to ten cases per million population.
Anastasia P Athanasoulia-Kaspar +2 more
doaj +1 more source
Binge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report
Frontiers in Psychiatry, 2022 Prolactinomas are the most prevalent functional pituitary adenomas. They are usually treated clinically with dopamine agonists. The most widely used and suitable drug is cabergoline (CAB), a specific D2 dopamine agonists.
Ana Carolina Correa e Castro +7 more
doaj +1 more source
TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg
Frontiers in Pharmacology, 2018 Trace-amine associated receptor 1 (TAAR1) is the best-characterized member of the family of TAARs. TAAR1 is broadly expressed in the brain, especially within the monoaminergic systems.
Jian-Feng Liu, Jian-Feng Liu, Jun-Xu Li
doaj +1 more source
Prolactinomas Resistant to Treatment With Dopamine Agonists: Long-Term Follow-Up of Six Cases
Frontiers in Endocrinology, 2018 Introduction: Prolactinomas are preferentially treated with dopamine agonists. However, a few adenomas are resistant to this treatment.Objective: To evaluate the characteristics of patients with resistance to dopamine agonists in the long-term.Method: A ...
Maria de Fátima de Magalhães Gonzaga +11 more
doaj +1 more source
Effects of L-Dopa and Dopamine D2 Agonists on Recollection and Familiarity in Idiopathic Nondementing Parkinson’s Disease [PDF]
, 2011 Idiopathic nondementing Parkinson’s disease (PD) is marked by progressive loss of dopaminergic neurons in the substantia nigra pars compacta and ventral tegmental area.
Edelstyn
core +1 more source
Dopamine-Agonist Induced Cerebrospinal Fluid Rhinorrhea; a Case Report
Journal of Cancer and Allied Specialties, 2021 Introduction: Prolactinomas are the most common pituitary adenomas. Medical therapy with dopamine agonists (DA) is the mainstay of treatment and rarely requires surgical manipulation.
Hira Irfan +5 more
doaj +1 more source
Dopamine receptor subtypes and ingestive behaviour [PDF]
, 1999 Both centrally and systemically administered dopamine agonists and antagonists decrease ingestive behaviour. The aim of this thesis was to examine whether drugs acting at different receptor subtypes decreased intake in different ways.
Genn, Rachel F., Genn, R.F.
core
Experience with Dopamine Agonists in the Treatment of Prolactinomas
Acta Medica Lituanica, 2022 The article is devoted to the conservative treatment of hyperprolactinemia of tumor origin. Cabergoline is considered as an effective treatment not only for microadenomas but also for large pituitary tumors which is illustrated by the clinical case of ...
Nadiya Barabash, Tetiana M. Tykhonova
doaj +1 more source
Development of novel ligands influencing neurotransmission in the central nervous system [PDF]
, 2007 The development of novel drugs targeting GPCRs is of particular interest since modulation of subfamilies of this receptor class highly influences neurotransmission in the central nervous system.
Sasse, Britta Caroline
core
Modulation of Adenylyl Cyclase Activity in Rat Striatal Homogenate by Dopaminergic Receptors
Journal of Pharmacological Sciences, 2008 We have characterized the modulation of adenylyl cyclase (AC) activity by ligands of dopaminergic receptors in rat striatal homogenate and compared the results with receptor-ligand binding affinities.
Argo Vonk, Reet Reinart, Ago Rinken
doaj +1 more source